Pnd30 Cost-Utility Analysis of Lacosamide Adjunctive Therapy in the Treatment of Partial-Onset Seizures in Epileptic Patients in Belgium

Simoens, Steven; Dedeken, Peter; Naeyer, Ludwig De; Benhaddi, H.

doi:10.1016/s1098-3015(11)72611-0

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pediatric population remains largely unstudied and should be addressed as a distinct subgroup of patients with special attention to adverse events.The relative efficacy and safety of lacosamide in comparison to alternative AEDs has not been prospectively studied and is critically important to best inform clinical decision-making.Three cost-effectiveness analyses (European health care payer perspective) were found (Simoens et al, 2010; Soini, Martikainen & Vanoli, 2009; Bolin, Berggren & Forsgren, 2010). These analyses do not have direct applicability to the Canadian health care system.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis

Sawh

Newman

Deshpande

et al. 2013

PeerJ

View full text Add to dashboard Cite

Background. The relative efficacy and safety of lacosamide as adjunctive therapy compared to other antiepileptic drugs has not been well established.Objective. To determine if lacosamide provides improved efficacy and safety, reduced length of hospital stay and improved quality of life compared with other anti-epileptic therapies for adults with partial-onset seizures.Data Sources. A systematic review of the medical literature using Medline (1946–Week 4, 2012), EMBASE (1980–Week 3, 2012), Cochrane Central Register of Controlled Trials (Issue 1 of 12, January 2012). Additional studies were identified (through to February 7, 2012) by searching bibliographies, the FDA drug approval files, clinical trial registries and major national and international neurology meeting abstracts. No restrictions on publication status or language were applied.Study Selection. Randomized controlled trials of lacosamide in adults with partial-onset seizures were included.Data Extraction. Study selection, extraction and risk of bias assessment were performed independently by two authors. Authors of studies were contacted for missing data.Data Synthesis. All pooled analyses used the random effects model.Results. Three trials (1311 patients) met inclusion criteria. Lacosamide increased the 50% responder rate compared to placebo (RR 1.68 [95% CI 1.36 to 2.08]; I2 = 0%). Discontinuation due to adverse events was statistically significantly higher in the lacosamide arm (RR3.13 [95% CI 1.94 to 5.06]; I2 = 0%). Individual adverse events (ataxia, dizziness, fatigue, and nausea) were also significantly higher in the lacosamide group.Limitations. All dosage arms from the included studies were pooled to make a single pair-wise comparison to placebo. Selective reporting of outcomes was found in all of the included RCTs.Conclusions. Lacosamide as adjunctive therapy in patients with partial-onset seizures increases the 50% responder rate but with significantly more adverse events compared to the placebo.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Three cost-effectiveness analyses (European health care payer perspective) were found (Simoens et al, 2010; Soini, Martikainen & Vanoli, 2009; Bolin, Berggren & Forsgren, 2010). These analyses do not have direct applicability to the Canadian health care system.…”

Section: Discussionmentioning

confidence: 99%

Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis

Sawh

Newman

Deshpande

et al. 2013

PeerJ

View full text Add to dashboard Cite

show abstract

“…Few studies have focused on adjunctive therapy with lacosamide for partial-onset seizures in adult patients: the researcher identified 32 citations, but only nine studies were included in the review: three randomized controlled trials published in peer-reviewed journals14-16, three open-label extension studies published as abstracts (Ben-Menachem et al, 2009;Rosenfeld et al, 2009;Faught et al, 2010;Husain et al, 2010), one economic evaluation published in a peer-reviewed journal (Bolin et al, 2010), and two economic evaluations published as abstracts (one of which also included a budget impact analysis) (Simoens et al, 2010;Soini et al, 2009). Studies were excluded because of one or more of the following reasons: disease other than refractory epilepsy; study not involving lacosamide; study of intravenous lacosamide; study of pharmacodynamic and/or pharmacokinetic profile of lacosamide; literature review rather than original study; case study.…”

Section: Search Resultsmentioning

confidence: 99%

Novel Treatment of Epilepsy

Foyaca-Sibat¹

2011

View full text Add to dashboard Cite

soon after he assessed his first epileptic patient. He became specialist in neurology in 1975 and higher level specialist in 1984. He is married and has three daughters and one son; his one daughter tragically passed away in 1979. Currently Dr. Foyaca has been an Associate Professor of Walter Sisulu University for more than 14 years, and he is also Master in Sciences and Associate Investigator of Cuban Academy of Sciences. He is a member of 15 Medical Societies from all over the world; he presented more than 350 papers in different scientific events and he published more than 70 manuscripts in peer-review journals. He

show abstract

“…Three economic evaluations used a similar design to determine the cost-effectiveness of lacosamide from the health care payer perspective in Sweden, Finland and Belgium (Bolin et al, 2010;Simoens et al, 2010;Soini et al, 2009). These studies compared standard AED therapy plus lacosamide with standard AED therapy alone in treating partial-onset seizures with or without secondary generalization in epilepsy patients from 16 years who are uncontrolled on current treatment with at least two AEDs.…”

Section: Cost-effectivenessmentioning

confidence: 99%

“…The authors applied the conservative assumption of using generic drug prices in the analysis. It should be noted that this analysis focused on drug costs only and did not consider the fact that lacosamide reduces costs of seizure management and withdrawal, as demonstrated by the economic evaluations (Bolin et al, 2010;Simoens et al, 2010;Soini et al, 2009). The results indicated that the expected annual drug budget increase due to the introduction of lacosamide would rise to € 232,600 in 2012.…”

Section: Budget Impactmentioning

confidence: 99%

Health Technology Assessment of Lacosamide as Adjunctive Therapy for Partial-Onset Epileptic Seizures

Simoens¹

2011

Novel Treatment of Epilepsy

View full text Add to dashboard Cite

Pnd30 Cost-Utility Analysis of Lacosamide Adjunctive Therapy in the Treatment of Partial-Onset Seizures in Epileptic Patients in Belgium

Cited by 5 publications

References 0 publications

Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis

Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis

Novel Treatment of Epilepsy

Health Technology Assessment of Lacosamide as Adjunctive Therapy for Partial-Onset Epileptic Seizures

Contact Info

Product

Resources

About